YTEN Pengajuan SEC - Yield10 Bioscience, Inc.- Laporan Tahunan, Pernyataan Kuasa, Prospektus

Mga Batayang Estadistika

LEI	5493008TC8RB9CSBE696
CIK	1121702

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Yield10 Bioscience, Inc.

SEC Filings (Chronological Order)

Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.

December 6, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Costs Associated with Exit or Disposal Activities, Bankruptcy or Receivership UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 6, 2024 YIELD10 BIOSCIENCE, INC.
November 22, 2024	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 21, 2024 YIELD10 BIOSCIENCE, INC.
November 12, 2024	EX-10.1	SECURED PROMISSORY NOTE Exhibit 10.1 SECURED PROMISSORY NOTE $3,000,000 September 5, 2024 This Secured Promissory Note (this “Note”) is entered into and effective as of the date first written above. RECITALS WHEREAS, Yield10 Bioscience, Inc., a Delaware corporation (the “Company”), Yield10 Oilseeds Inc., a company organized under the laws of Canada (“Oilseeds”), and Nuseed Nutritional US Inc., a Delaware corporation (“Nu
November 12, 2024	EX-99.1	Yield10 Bioscience Announces Adjournment of Special Meeting of Stockholders to Solicit Sufficient Votes in Favor of the Key Proposals; Special Meeting Adjourned to Thursday, November 14, 2024 Yield10 Bioscience Announces Adjournment of Special Meeting of Stockholders to Solicit Sufficient Votes in Favor of the Key Proposals; Special Meeting Adjourned to Thursday, November 14, 2024 WOBURN, Mass.
November 12, 2024	EX-10.2	AMENDMENT NO. 1 TO SECURED PROMISSORY NOTE Exhibit 10.2 AMENDMENT NO. 1 TO SECURED PROMISSORY NOTE This AMENDMENT NO. 1 TO SECURED PROMISSORY NOTE (this “Amendment”) is made as of November , 2024, by and among Yield10 Bioscience, Inc., a Delaware corporation (the “Company”), Yield10 Oilseeds Inc., a company organized under the laws of Canada (“Oilseeds”), Yield10 Bioscience Securities Corp. (f/k/a Metabolix Securities Corp.), a Massachuset
November 12, 2024	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 8, 2024 YIELD10 BIOSCIENCE, INC.
October 31, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 29, 2024 YIELD10 BIOSCIENCE, INC.
October 16, 2024	DEFM14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registran UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission (as permitted by Rule 14a-6(e)(2)) ý Definitive
October 3, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 30, 2024 YIELD10 BIOSCIENCE, INC.
October 3, 2024	EX-10.1	Second Amendment to Employment Agreement Exhibit 10.1 Second Amendment to Employment Agreement This Amendment (the “Second Amendment”) is entered into as of September 30, 2024, by and between (the “Executive”) and Yield10 Bioscience, Inc. (the “Company” or “Yield10”), as parties to the employment agreement dated March 28, 2017, as previously amended on December 6, 2023 (the “First Amendment,” and as so amended, the “Agreement”). The Agre
October 2, 2024	EX-FILING FEES	Calculation of Filing Fee Tables Schedule 14A (Form Type) Yield10 Bioscience, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Transaction Value Exhibit 107 Calculation of Filing Fee Tables Schedule 14A (Form Type) Yield10 Bioscience, Inc.
October 2, 2024	PREM14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registran UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: ý Preliminary Proxy Statement o Confidential, for Use of the Commission (as permitted by Rule 14a-6(e)(2)) o Definitive
September 9, 2024	8-K	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 6, 2024 YIELD10 BIOSCIENCE, INC.
August 14, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-33133 YIELD10 BIOSCIENCE, I
July 29, 2024	424B3	YIELD10 BIOSCIENCE, INC. 265,928 SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF OUTSTANDING WARRANTS TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(3) Registration No. 333-278930 PROSPECTUS YIELD10 BIOSCIENCE, INC. 265,928 SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF OUTSTANDING WARRANTS This prospectus relates to the proposed resale from time to time, by the selling security holders identified in this prospectus, of up to 265,928 shares of Yield10 Bioscience, Inc. (the “Company”), common
July 23, 2024	8-K	Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 23, 2024 YIELD10 BIOSCIENCE, INC.
July 22, 2024	CORRESP	Yield10 Bioscience, Inc. 19 Presidential Way Woburn, Massachusetts 01801 Yield10 Bioscience, Inc. 19 Presidential Way Woburn, Massachusetts 01801 July 22, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Nicholas O'Leary Re: Yield10 Bioscience, Inc. (the "Company") Registration Statement on Form S-1, as amended (the "Registration Statement") File No. 333-278930 Dear Mr. O'Leary: Pursu
July 17, 2024	EX-99.1	Yield10 Bioscience Grants Nufarm a Commercial License to Omega-3 Assets for Producing Oil in Camelina, and Yield10 and Nufarm sign a Memorandum of Understanding for Sale of Assets - Nufarm to pay up to USD $5 million in consideration for the license Yield10 Bioscience Grants Nufarm a Commercial License to Omega-3 Assets for Producing Oil in Camelina, and Yield10 and Nufarm sign a Memorandum of Understanding for Sale of Assets - Nufarm to pay up to USD $5 million in consideration for the license -The parties will negotiate the sale of essentially all of Yield10’s assets to Nufarm WOBURN, Mass.
July 17, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 17, 2024 YIELD10 BIOSCIENCE, IN UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 17, 2024 YIELD10 BIOSCIENCE, INC.
June 12, 2024	EX-3.1	CERTIFICATE OF AMENDMENT AMENDED AND RESTATED CERTIFICATE OF INCORPORATION YIELD10 BIOSCIENCE, INC. Pursuant to Section 242 of the General Corporation Law of the State of Delaware Exhibit 3.1 CERTIFICATE OF AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF YIELD10 BIOSCIENCE, INC. Pursuant to Section 242 of the General Corporation Law of the State of Delaware YIELD10 BIOSCIENCE, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify as follows: 1.The name of the
June 12, 2024	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 12, 2024 YIELD10 BIOSCIENCE, INC.
June 10, 2024	EX-10.1	YIELD10 BIOSCIENCE, INC. AMENDED AND RESTATED 2018 STOCK OPTION AND INCENTIVE PLAN Exhibit 10.1 YIELD10 BIOSCIENCE, INC. AMENDED AND RESTATED 2018 STOCK OPTION AND INCENTIVE PLAN 1.DEFINITIONS. Unless otherwise specified or unless the context otherwise requires, the following terms, as used in this Yield10 Bioscience, Inc. 2018 Stock Option and Incentive Plan, have the following meanings: Administrator means the Board of Directors, unless it has delegated power to act on its beh
June 10, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 7, 2024 YIELD10 BIOSCIENCE, INC.
May 28, 2024	S-1/A	As filed with the Securities and Exchange Commission on May 28, 2024 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on May 28, 2024 Registration Statement No.
May 23, 2024	SC 13D/A	YTEN / Yield10 Bioscience, Inc. / SCHULER JACK W Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.
May 15, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 15, 2024 YIELD10 BIOSCIENCE, INC.
May 15, 2024	EX-99.1	Yield10 Bioscience Announces Delisting from Nasdaq Exhibit 99.1 Yield10 Bioscience Announces Delisting from Nasdaq WOBURN, Mass. – May 15, 2024 – Yield10 Bioscience, Inc. (Nasdaq:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today announced that Company has received a final delisting notice from Nasdaq. The delisting is a result of failure to regain compliance with the minimum stockholders’ equity requirement for continue
May 15, 2024	EX-99.1	Yield10 Bioscience Announces First Quarter 2024 Financial Results -Earns $1 million in milestone payments from Vision Bioenergy Oilseeds Yield10 Bioscience Announces First Quarter 2024 Financial Results -Earns $1 million in milestone payments from Vision Bioenergy Oilseeds WOBURN, Mass.
May 15, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-33133 YIELD10 BIOSCIENCE,
May 15, 2024	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2024 YIELD10 BIOSCIENCE, INC.
May 9, 2024	RW	Yield10 Bioscience, Inc. 19 Presidential Way Woburn, MA 01801 Yield10 Bioscience, Inc. 19 Presidential Way Woburn, MA 01801 May 9, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Yield10 Bioscience, Inc. Withdrawal of Registration Statement on Form S-1 File No. 333-279109 Ladies and Gentlemen: Pursuant to Rule 477 promulgated under the Securities Act of 1933, as amended (the
May 7, 2024	S-1/A	As filed with the Securities and Exchange Commission on May 7, 2024 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on May 7, 2024 Registration Statement No.
May 3, 2024	S-1	As filed with the Securities and Exchange Commission on May 3, 2024 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on May 3, 2024 Registration Statement No.
May 3, 2024	EX-FILING FEES	Filing Fee Table. EXHIBIT 107 Calculation of Filing Fee Tables S-1 (Form Type) Yield10 Bioscience, Inc.
May 1, 2024	EX-3.1	CERTIFICATE OF AMENDMENT TO EFFECT REVERSE STOCK SPLIT Exhibit 3.1 CERTIFICATE OF AMENDMENT TO EFFECT REVERSE STOCK SPLIT Pursuant to Section 242 of the General Corporation Law of the State of Delaware, Yield10 Bioscience, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), does hereby certify as follows: 1.The name of the Corporation is Yield10 Bioscience, Inc. 2.The Certificate of Incorporation of
May 1, 2024	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 1, 2024 YIELD10 BIOSCIENCE, INC.
May 1, 2024	EX-99.1	Yield10 Bioscience Announces 1-for-24 Reverse Stock Split Yield10 Bioscience Announces 1-for-24 Reverse Stock Split WOBURN, Mass. – May 1, 2024 – Yield10 Bioscience, Inc. (Nasdaq:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today announced that it will effect a 1-for-24 reverse stock split of its common stock, following stockholder approval of the reverse stock split at its special stockholder meeting held on April 26, 2024. Th
April 30, 2024	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 26, 2024 YIELD10 BIOSCIENCE, INC.
April 29, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registran UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ý Defin
April 25, 2024	EX-FILING FEES	Filing Fee Table** Exhibit 107 Calculation of Filing Fee Tables S-1 (Form Type) Yield10 Bioscience, Inc.
April 25, 2024	S-1	As filed with the Securities and Exchange Commission on April 25, 2024 As filed with the Securities and Exchange Commission on April 25, 2024 Registration Statement No.
April 19, 2024	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registran UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: ý Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin
April 4, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin
April 2, 2024	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin
April 1, 2024	EX-10.5	Amendment to the Employment Agreement between the Company and Oliver Peoples dated December 6, 2023. Exhibit 10.5 Amendment to Employment Agreement This Amendment (“the Amendment”) is made by Oliver Peoples and Yield10 Bioscience, Inc. (the “Company” or “Yield10”), parties to the employment agreement dated March 28, 2017 (“the Agreement”). The Agreement is amended as follows: Commencing on December 4, 2023, Oliver Peoples' weekly base salary will be temporarily adjusted to $684 per week. Subject
April 1, 2024	EX-10.11	Amendment to the Employment Agreement between the Company and Kristi Snell dated December 6, 2023. Exhibit 10.11 Amendment to Employment Agreement This Amendment (“the Amendment”) is made by Kristi Snell and Yield10 Bioscience, Inc. (the “Company” or “Yield10”), parties to the employment agreement dated March 28, 2017 (“the Agreement”). The Agreement is amended as follows: Commencing on December 4, 2023, Kristi Snell's weekly base salary will be temporarily adjusted to $684 per week. Subject to
April 1, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 1, 2024 YIELD10 BIOSCIENCE, INC.
April 1, 2024	EX-10.9	Amendment to the Employment Agreement between the Company and Lynne Brum dated December 6, 2023. Exhibit 10.9 Amendment to Employment Agreement This Amendment (“the Amendment”) is made by Lynne Brum and Yield10 Bioscience, Inc. (the “Company” or “Yield10”), parties to the employment agreement dated March 28, 2017 (“the Agreement”). The Agreement is amended as follows: Commencing on December 4, 2023, Lynne Brum's weekly base salary will be temporarily adjusted to $684 per week. Subject to the
April 1, 2024	EX-10.7	Amendment to the Employment Agreement between the Company and Charles B. Haaser dated December 6, 2023. Exhibit 10.7 Amendment to Employment Agreement This Amendment (“the Amendment”) is made by Charles B. Haaser and Yield10 Bioscience, Inc. (the “Company” or “Yield10”), parties to the employment agreement dated March 28, 2017 (“the Agreement”). The Agreement is amended as follows: Commencing on December 4, 2023, Charles B. Haaser's weekly base salary will be temporarily adjusted to $684 per week. S
April 1, 2024	EX-99.1	Yield10 Bioscience Announces Fourth Quarter and Full Year 2023 Financial Results -Granted global commercial license to Vision Bioenergy for Camelina addressing the biofuel market -Advanced regulatory and seed scale-up program for omega-3 Camelina -E3 Yield10 Bioscience Announces Fourth Quarter and Full Year 2023 Financial Results -Granted global commercial license to Vision Bioenergy for Camelina addressing the biofuel market -Advanced regulatory and seed scale-up program for omega-3 Camelina -E3902 oil trait in Camelina cleared by regulatory authority for planting in Canada -Management will host a conference call today at 4:30 p.
April 1, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTI 40Use these links to rapidly review the document TABLE OF CONTENTS Index to Consolidated Financial Statements UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
March 29, 2024	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2024 YIELD10 BIOSCIENCE, INC.
March 22, 2024	EX-4.1	Form of Warrant Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
March 22, 2024	EX-10.1	Exchange Agreement, dated as of March 22, 2024, by and among the Company and the warrantholders party thereto. Exhibit 10.1 YIELD10 BIOSCIENCE, INC. March 22, 2024 Holder of Common Stock Purchase Warrants Re: Inducement Offer to Exercise Common Stock Purchase Warrants Dear Holder: Yield10 Bioscience, Inc. (the “Company”) is pleased to offer to you the opportunity to exercise all of the warrants to purchase shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”), set forth on Ex
March 22, 2024	EX-4.1	Form of Warrant Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
March 22, 2024	EX-10.1	Form of Exchange Agreement, dated as of March 22, 2024, by and among the Company and the warrantholders party thereto Exhibit 10.1 YIELD10 BIOSCIENCE, INC. March 22, 2024 Holder of Common Stock Purchase Warrants Re: Inducement Offer to Exercise Common Stock Purchase Warrants Dear Holder: Yield10 Bioscience, Inc. (the “Company”) is pleased to offer to you the opportunity to exercise all of the warrants to purchase shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”), set forth on Ex
March 22, 2024	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2024 YIELD10 BIOSCIENCE, INC.
March 22, 2024	8-K/A	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2024 YIELD10 BIOSCIENCE, INC.
February 26, 2024	8-K	Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 22, 2024 YIELD10 BIOSCIENCE, INC.
February 16, 2024	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 13, 2024 YIELD10 BIOSCIENCE, INC.
February 14, 2024	EX-99.1	Yield10 Bioscience Grants Global License to VISION Bioenergy Oilseeds for Herbicide Tolerant Camelina Cultivated for the Production of Biofuel Feedstock Global License of Industry-Leading Elite Herbicide Tolerant Camelina Accelerates Biofuel Feedstoc Yield10 Bioscience Grants Global License to VISION Bioenergy Oilseeds for Herbicide Tolerant Camelina Cultivated for the Production of Biofuel Feedstock Global License of Industry-Leading Elite Herbicide Tolerant Camelina Accelerates Biofuel Feedstock Production WOBURN, Mass.
February 14, 2024	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 9, 2024 YIELD10 BIOSCIENCE, INC.
February 8, 2024	EX-99.1	Yield10 Bioscience Provides an Update on its Omega-3 Camelina Program -Prioritizes Activities to Advance Omega-3 Camelina Program in 2024 -Reports Completion of Contra Season Production of Omega-3 Camelina Seed in Chile - Company also Provides Update Yield10 Bioscience Provides an Update on its Omega-3 Camelina Program -Prioritizes Activities to Advance Omega-3 Camelina Program in 2024 -Reports Completion of Contra Season Production of Omega-3 Camelina Seed in Chile - Company also Provides Update on Nasdaq Status WOBURN, Mass.
February 8, 2024	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 7, 2024 YIELD10 BIOSCIENCE, INC.
February 6, 2024	EX-16.1	Letter from RSM US LLP dated February 5, 2024. 80 City Square Boston, MA 02129 T +1 617 912 9000 F +1 617 912 9001 www.rsmus.com February 5, 2024 Securities and Exchange Commission Washington, D.C. 20549 Commissioners: We have read Yield10 Bioscience, Inc.’s statements included under Item 4.01 of its Form 8-K filed on February 5, 2024 and we agree with such statements concerning our firm.
February 6, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 2, 2024 YIELD10 BIOSCIENCE, UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 2, 2024 YIELD10 BIOSCIENCE, INC.
December 6, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 30, 2023 YIELD10 BIOSCIENCE UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 30, 2023 YIELD10 BIOSCIENCE, INC.
November 17, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 15, 2023 YIELD10 BIOSCIENCE UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 15, 2023 YIELD10 BIOSCIENCE, INC.
November 15, 2023	EX-99.2	USDA-APHIS Determines that Yield10 Bioscience’s Stacked Herbicide Tolerant Camelina May Be Planted and Bred in the United States -Herbicide Technology Critical to Enabling Large-Acreage Adoption of Camelina in North America Exhibit 99.2 USDA-APHIS Determines that Yield10 Bioscience’s Stacked Herbicide Tolerant Camelina May Be Planted and Bred in the United States -Herbicide Technology Critical to Enabling Large-Acreage Adoption of Camelina in North America WOBURN, Mass. – November 15, 2023 – Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that t
November 15, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 15, 2023 YIELD10 BIOSCIENCE UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 15, 2023 YIELD10 BIOSCIENCE, INC.
November 15, 2023	EX-99.1	USDA-APHIS Determines that Yield10 Bioscience’s Glufosinate Tolerant Camelina May Be Planted and Bred in the United States -Yield10 Achieves a Significant Milestone in the Development of Camelina as a Commercial Crop for Producing Biofuels and Omega- Exhibit 99.1 USDA-APHIS Determines that Yield10 Bioscience’s Glufosinate Tolerant Camelina May Be Planted and Bred in the United States -Yield10 Achieves a Significant Milestone in the Development of Camelina as a Commercial Crop for Producing Biofuels and Omega-3 Oils -On Track for Commercial Launch of Glufosinate Tolerant Camelina as early as 2025 WOBURN, Mass. – November 15, 2023 – Yield10 Bios
November 14, 2023	EX-99.1	Yield10 Bioscience Announces Third Quarter 2023 Financial Results -Establishes "Camelina Seed Genetics to Biofuel" Platform -Advances Herbicide Tolerant Camelina Varieties toward Commercialization -Exercises Option to Finalize Exclusive, Global Comme Yield10 Bioscience Announces Third Quarter 2023 Financial Results -Establishes "Camelina Seed Genetics to Biofuel" Platform -Advances Herbicide Tolerant Camelina Varieties toward Commercialization -Exercises Option to Finalize Exclusive, Global Commercial License to Advanced Omega-3 Technology -Management will host a conference call today at 4:30 pm (ET) WOBURN, Mass.
November 14, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 14, 2023 YIELD10 BIOSCIENCE UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 14, 2023 YIELD10 BIOSCIENCE, INC.
November 14, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-33133 YIELD10 BIOSCIEN
October 31, 2023	EX-99.1	Yield10 Bioscience and BioMar Aim to Grow Fish Oil on Land Yield10 Bioscience and BioMar Group have signed an LOI to form a long-term partnership to commercialize a Camelina crop containing enriched levels of EPA and DHA equal to fish oil. After a de Yield10 Bioscience and BioMar Aim to Grow Fish Oil on Land Yield10 Bioscience and BioMar Group have signed an LOI to form a long-term partnership to commercialize a Camelina crop containing enriched levels of EPA and DHA equal to fish oil.
October 31, 2023	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 25, 2023 YIELD10 BIOSCIENCE, INC.
October 19, 2023	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2023 YIELD10 BIOSCIENCE, INC.
October 19, 2023	EX-99.1	Yield10 Bioscience Exercises Option to Finalize an Exclusive, Global Commercial License to Advanced Omega-3 Camelina Technology from Rothamsted Research Exhibit 99.1 Yield10 Bioscience Exercises Option to Finalize an Exclusive, Global Commercial License to Advanced Omega-3 Camelina Technology from Rothamsted Research WOBURN, Mass. – October 18, 2023 – Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that the Company has exercised its option to finalize an exclusive global, com
October 11, 2023	SC 13D	YTEN / Yield10 Bioscience Inc / SCHULER JACK W Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.
September 25, 2023	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 25, 2023 YIELD10 BIOSCIENCE, INC.
September 11, 2023	EX-99.1	Today www.yield10bio.com NasdaqCM: YTEN Yield10 Bioscience, Inc. Sept. 11-13, 2023 Sustainable Growth Starts with a Seed 25th Annual H. C. Wainwright Global Investment Conference Recorded on Sept. 6, 2023 Today Safe Harbor Statement 2 The statements ytenhcwconfslidedeck9x0 Today www.yield10bio.com NasdaqCM: YTEN Yield10 Bioscience, Inc. Sept. 11-13, 2023 Sustainable Growth Starts with a Seed 25th Annual H. C. Wainwright Global Investment Conference Recorded on Sept. 6, 2023 Today Safe Harbor Statement 2 The statements made by Yield10 Bioscience, Inc. (the “Company,” “we,” “our” or “us”) herein regarding the Company and its business may be for
September 11, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 11, 2023 YIELD10 BIOSCIENC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 11, 2023 YIELD10 BIOSCIENCE, INC.
August 14, 2023	EX-99.1	Yield10 Bioscience Announces Second Quarter 2023 Financial Results -Harvesting underway for contracted winter and spring Camelina acres for the biofuels market -Reported positive results in first field tests of stacked herbicide tolerant Camelina -Fi Yield10 Bioscience Announces Second Quarter 2023 Financial Results -Harvesting underway for contracted winter and spring Camelina acres for the biofuels market -Reported positive results in first field tests of stacked herbicide tolerant Camelina -Filed a request for regulatory status review with USDA-APHIS for omega-3 (EPA) Camelina -Strengthened balance sheet with recent financing -Management will host a conference call today at 4:30 pm (ET) WOBURN, Mass.
August 14, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-33133 YIELD10 BIOSCIENCE, I
August 14, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 14, 2023 YIELD10 BIOSCIENCE, INC.
August 11, 2023	424B4	YIELD10 BIOSCIENCE, INC. 5,750,000 Units consisting of 5,750,000 Shares of Common Stock and Common Warrants to Purchase 5,750,000 Shares of Common Stock 5,750,000 Shares of Common Stock Underlying Common Warrants TABLE OF CONTENTS Filed pursuant to Rule 424(b)(4) Registration No. 333-273240 PROSPECTUS YIELD10 BIOSCIENCE, INC. 5,750,000 Units consisting of 5,750,000 Shares of Common Stock and Common Warrants to Purchase 5,750,000 Shares of Common Stock 5,750,000 Shares of Common Stock Underlying Common Warrants We are offering on a reasonable best efforts basis 5,750,000 units (the “units”), each unit con
August 11, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2023 YIELD10 BIOSCIENCE, UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2023 YIELD10 BIOSCIENCE, INC.
August 11, 2023	EX-99.1	Yield10 Bioscience Announces Pricing of $3.7 Million Public Offering Exhibit 99.1 Yield10 Bioscience Announces Pricing of $3.7 Million Public Offering WOBURN, Mass. – August 11, 2023 – Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced the pricing of its public offering of 5,750,000 units at a public offering price of $0.65 per unit. Each unit consists of one share of common stock and one warrant
August 11, 2023	EX-10.1	Form of Securities Purchase Agreement, dated as of August 10, 2023, by and between the Company and each investor party thereto. Exhibit 10.1 CONFIDENTIAL August 10, 2023 Dr. Oliver P. Peoples, Ph.D. President & Chief Executive Officer Yield10 Bioscience, Inc. 19 Presidential Way, Suite 201 Woburn, MA 01801 Dear Dr. Peoples, This agreement (the “Agreement”) constitutes the agreement between Yield10 Bioscience, Inc., a Delaware corporation (the “Company”), Maxim Group, LLC (“Maxim” or the “Lead Manager”), and Lake Street Cap
August 8, 2023	CORRESP	MAXIM GROUP LLC 300 Park Avenue, 16th Floor New York, New York 10022 MAXIM GROUP LLC 300 Park Avenue, 16th Floor New York, New York 10022 August 8, 2023 VIA EDGAR CORRESPONDENCE U.
August 7, 2023	CORRESP	August 7, 2023 August 7, 2023 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Jessica Ansart Re: Yield10 Bioscience, Inc. (the “Company”) Registration Statement Filed on Form S-1, as amended (the “Registration Statement”) File No. 333-273240 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, th
August 2, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2023 YIELD10 BIOSCIENCE, UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2023 YIELD10 BIOSCIENCE, INC.
August 2, 2023	EX-1.1	Placement Agency Agreement Exhibit 1.1 CONFIDENTIAL August [ ], 2023 Dr. Oliver P. Peoples, Ph.D. President & Chief Executive Officer Yield10 Bioscience, Inc. 19 Presidential Way, Suite 201 Woburn, MA 01801 Dear Dr. Peoples, This agreement (the “Agreement”) constitutes the agreement between Yield10 Bioscience, Inc., a Delaware corporation (the “Company”), Maxim Group, LLC (“Maxim” or the “Lead Manager”), and Lake Street Cap
August 2, 2023	EX-4.9	Form of Common Stock Purchase Warrant Exhibit 4.9 FORM OF COMMON STOCK PURCHASE WARRANT YIELD10 BIOSCIENCE, INC. Warrant Shares: [ · ]1 Issue Date: [·], 2023 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, CEDE & CO. or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Issue Date
August 2, 2023	S-1/A	As filed with the Securities and Exchange Commission on August 2, 2023. TABLE OF CONTENTS As filed with the Securities and Exchange Commission on August 2, 2023.
August 2, 2023	EX-99.1	Today NasdaqCM : YTEN Yield10 Bioscience, Inc. August 2023 Investor Presentation Sustainable Growth Starts with a Seed Exhibit 99.1 Today NasdaqCM : YTEN Yield10 Bioscience, Inc. August 2023 Investor Presentation Sustainable Growth Starts with a Seed Today Safe Harbor Statement 2 The statements made by Yield10 Bioscience, Inc. (the “Company,” “we,” “our” or “us”) herein regarding the Company and its bus ine ss may be forward - looking in nature and are made pursuant to the safe harbor provisions of the Private Sec
August 2, 2023	EX-10.21	Securities Purchase Agreement, dated as of August 1, 2023, by and between Yield10 Bioscience, Inc. and the Purchasers named therein. Exhibit 10.21 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of August [ ], 2023 between Yield10 Bioscience, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditi
August 2, 2023	EX-4.8	Form of Pre-funded Warrant Exhibit 4.8 FORM OF PRE-FUNDED COMMON STOCK PURCHASE WARRANT YIELD10 BIOSCIENCE, INC. Warrant Shares: [ l ]1 Issue Date and Initial Exercise Date: [ l ], 2023 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, CEDE & CO. or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter
August 2, 2023	EX-FILING FEES	Filing fee table. Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Yield10 Bioscience, Inc.
August 2, 2023	EX-4.10	Form of Warrant Agency Agreement Exhibit 4.10 YIELD10 BIOSCIENCE, INC. and EQUINITI TRUST COMPANY, LLC, as Warrant Agent Warrant Agency Agreement Dated as of August , 2023 WARRANT AGENCY AGREEMENT WARRANT AGENCY AGREEMENT, dated as of August , 2023 (“Agreement”), between Yield10 Bioscience, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), and Equiniti Trust Company, LLC (the “Warrant Agent”).
July 18, 2023	424B3	YIELD10 BIOSCIENCE, INC. 1,006,710 SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF OUTSTANDING WARRANTS TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(3) Registration No. 333-273070 PROSPECTUS YIELD10 BIOSCIENCE, INC. 1,006,710 SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF OUTSTANDING WARRANTS This prospectus relates to the proposed resale from time to time, by the selling security holders identified in this prospectus of up to 1,006,710 shares of Yield10 Bioscience, Inc. (the “Company”), comm
July 14, 2023	EX-FILING FEES	Filing fee table. Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Yield10 Bioscience, Inc.
July 14, 2023	S-1	As filed with the Securities and Exchange Commission on July 13, 2023. TABLE OF CONTENTS As filed with the Securities and Exchange Commission on July 13, 2023.
July 12, 2023	CORRESP	July 12, 2023 July 12, 2023 Via Edgar United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
July 12, 2023	S-1/A	As filed with the Securities and Exchange Commission on July 12, 2023 As filed with the Securities and Exchange Commission on July 12, 2023 Registration Statement No.
July 12, 2023	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Table Form S-1 (Form Type) Yield10 Bioscience, Inc.
July 7, 2023	DEL AM	YIELD10 BIOSCIENCE, INC. 19 Presidential Way Woburn, Massachusetts 01801 July 7, 2023 YIELD10 BIOSCIENCE, INC. 19 Presidential Way Woburn, Massachusetts 01801 July 7, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 RE: Yield10 Bioscience, Inc. Registration Statement on Form S-1 File No. 333-273070 To Whom It May Concern: Reference is made to the Registration Statement on Form S-1 (File No. 333-273070) fi
June 30, 2023	S-1	Power of Attorney (included in the signature pages to the Registration Statement). As filed with the Securities and Exchange Commission on June 30, 2023 Registration Statement No.
June 30, 2023	EX-FILING FEES	Calculation of Filing Fee Table Form S-1 (Form Type) Yield10 Bioscience, Inc. (Exact name of Registrant as Specified in its Charter) Exhibit 107 Calculation of Filing Fee Table Form S-1 (Form Type) Yield10 Bioscience, Inc.
June 14, 2023	EX-FILING FEES	Calculation of Filing Fee Table Form S-8 (Form Type) Yield10 Bioscience, Inc. (Exact name of Registrant as Specified in its Charter) Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Yield10 Bioscience, Inc.
June 14, 2023	S-8	As filed with the Securities and Exchange Commission on June 14, 2023 As filed with the Securities and Exchange Commission on June 14, 2023 Registration No.
May 30, 2023	EX-10.1	Amended and Restated 2018 Stock Option and Incentive Plan. Exhibit 10.1 YIELD10 BIOSCIENCE, INC. AMENDED AND RESTATED 2018 STOCK OPTION AND INCENTIVE PLAN 1.DEFINITIONS. Unless otherwise specified or unless the context otherwise requires, the following terms, as used in this Yield10 Bioscience, Inc. 2018 Stock Option and Incentive Plan, have the following meanings: Administrator means the Board of Directors, unless it has delegated power to act on its beh
May 30, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 25, 2023 YIELD10 BIOSCIENCE, INC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 25, 2023 YIELD10 BIOSCIENCE, INC.
May 26, 2023	SC 13D/A	YTEN / Yield10 Bioscience Inc / SCHULER JACK W Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.
May 19, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 18, 2023 YIELD10 BIOSCIENCE, INC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 18, 2023 YIELD10 BIOSCIENCE, INC.
May 12, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-33133 YIELD10 BIOSCIENCE,
May 10, 2023	EX-99.1	Yield10 Bioscience Announces First Quarter 2023 Financial Results -Executing commercial strategy for elite Camelina in the biofuels market -Met target for 2023 contracted spring Camelina acres -Permitting complete, planting underway for spring seed s Yield10 Bioscience Announces First Quarter 2023 Financial Results -Executing commercial strategy for elite Camelina in the biofuels market -Met target for 2023 contracted spring Camelina acres -Permitting complete, planting underway for spring seed scale-up and field testing program -Management will host a conference call today at 4:30 pm (ET) to review financial results and provide a corporate update WOBURN, Mass.
May 10, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 10, 2023 YIELD10 BIOSCIENCE, INC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 10, 2023 YIELD10 BIOSCIENCE, INC.
May 4, 2023	EX-99.1	Yield10 Bioscience Announces Pricing of $3.0 Million Registered Direct Offering and Concurrent Private Placement Exhibit 99.1 Yield10 Bioscience Announces Pricing of $3.0 Million Registered Direct Offering and Concurrent Private Placement WOBURN, Mass. – May 3, 2023 – Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that it has agreed to sell $3.0 million of its shares of common stock (or prefunded warrants in lieu thereof) in a register
May 4, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2023 YIELD10 BIOSCIENCE, INC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2023 YIELD10 BIOSCIENCE, INC.
May 4, 2023	EX-10.1	Securities Purchase Agreement, dated as of May 3, 2023, by and between the Company and the Purchasers. Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of May 3, 2023 between Yield10 Bioscience, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions se
May 4, 2023	EX-4.2	Form of Common Stock Purchase Warrant Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
May 4, 2023	424B5	Yield10 Bioscience, Inc. 931,600 Shares of Common Stock Pre-Funded Warrants to Purchase up to 75,110 Shares of Common Stock TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-254830 PROSPECTUS SUPPLEMENT (To Prospectus dated April 2, 2021) Yield10 Bioscience, Inc. 931,600 Shares of Common Stock Pre-Funded Warrants to Purchase up to 75,110 Shares of Common Stock We are offering to a certain institutional investor and to an existing investor an aggregate of 931,600 shares of our common stock, par v
May 4, 2023	EX-4.1	Form of Pre-Funded Common Stock Purchase Warrant Exhibit 4.1 FORM OF PRE-FUNDED COMMON STOCK PURCHASE WARRANT YIELD10 BIOSCIENCE, INC. Warrant Shares: [ · ] Issue Date and Initial Exercise Date: [ · ], 2023 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, a
May 3, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 3, 2023 YIELD10 BIOSCIENCE, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 3, 2023 YIELD10 BIOSCIENCE, INC.
May 1, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 27, 2023 YIELD10 BIOSCIENCE, I UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 27, 2023 YIELD10 BIOSCIENCE, INC.
May 1, 2023	EX-10.1	Securities Purchase Agreement, dated April 28, 2023, by and between the Company and MPC Investment LLC. Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (the “Agreement”) is made effective as of April 28, 2023, by and among Yield10 Bioscience, Inc., a Delaware corporation (the “Company”) and MPC Investment LLC, a Delaware limited liability company (the “Purchaser”). R E C I T A L S: WHEREAS, the Purchaser desires to purchase, and the Company desires to issue and sell the
May 1, 2023	EX-4.1	Senior Unsecured Convertible Promissory Note, dated as of April 28, 2023, between the Company and MPC Investment LLC Exhibit 4.1 THIS SECURITY (INCLUDING ANY SECURITIES ISSUABLE UPON CONVERSION) HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”) OR APPLICABLE STATE SECURITIES LAWS. THIS SECURITY (INCLUDING ANY SECURITIES ISSUABLE UPON CONVERSION) HAS BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO ITS DISTRIBUTION OR RESALE, AND MAY NOT BE SOLD, PLEDGED, OR OTHERWISE
April 6, 2023	DEF 14A	Definitive Proxy Statement on Schedule 14A for the annual meeting of our stockholders held on May 25, 2023, filed with the SEC on April 6, 2023; UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ý Defin
March 23, 2023	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Yield10 Bioscience, Inc.
March 23, 2023	S-8	As filed with the Securities and Exchange Commission on March 23, 2023 As filed with the Securities and Exchange Commission on March 23, 2023 Registration No.
March 14, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTI 40Use these links to rapidly review the document TABLE OF CONTENTS Index to Consolidated Financial Statements UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
March 14, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 14, 2023 YIELD10 BIOSCIENCE, I UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 14, 2023 YIELD10 BIOSCIENCE, INC.
March 14, 2023	EX-99.1	Yield10 Bioscience Announces Fourth Quarter and Full Year 2022 Financial Results -Executing strategy to build supply chain alliances for the production of low-carbon intensity Camelina feedstock oil for the biofuels market -Advancing development of h Yield10 Bioscience Announces Fourth Quarter and Full Year 2022 Financial Results -Executing strategy to build supply chain alliances for the production of low-carbon intensity Camelina feedstock oil for the biofuels market -Advancing development of herbicide tolerant Camelina varieties -Accelerating development of omega-3 Camelina -Management will host a conference call today at 4:30 p.
March 14, 2023	EX-10.18	Collaboration and Option Agreement, dated November 12, 2020, by and between the Company and Rothamsted Research Institute, as amended. Exhibit 10.18 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE THE INFORMATION IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. OPTION AGREEMENT ROTHAMSTED RESEARCH INSTITUTE THIS OPTION AGREEMENT (“AGREEMENT”) is made and entered into on the day that the second PARTY signs it below (“EF
March 14, 2023	EX-4.1	Exhibit 4.1 Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Yield10 Bioscience, Inc. (the “Company” or “we”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common stock, par value $0.01 per share. DESCRIPTION OF COMMON STOCK We are authorized to issue 60,000,000 shar
January 24, 2023	EX-1.1	Equity Distribution Agreement, dated January 23, 2023, by and between the Company and Maxim Group LLC. EX-1.1 2 tm234196d1ex1-1.htm EXHIBIT 1.1 Exhibit 1.1 YIELD10 BIOSCIENCE, INC. Up to $4,200,000 of Common Stock EQUITY DISTRIBUTION AGREEMENT January 23, 2023 Maxim Group LLC 300 Park Avenue, 16th Floor New York, New York 10022 Ladies and Gentlemen: Yield10 Bioscience, Inc., a Delaware corporation (the “Company”), proposes to issue and sell through Maxim Group LLC (the “Agent”), as sales agent, com
January 24, 2023	424B5	Up to $4,200,000 Common Stock Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-254830 PROSPECTUS SUPPLEMENT (To Prospectus dated April 2, 2021) Up to $4,200,000 Common Stock We have entered into an Equity Distribution Agreement with Maxim Group LLC, or Maxim, dated January 23, 2023, relating to the offer and sale of our Common Stock, par value $0.01 per share, offered by this prospectus supplement. In accordance
January 24, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 23, 2023 YIELD10 BIOSCIENCE, UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 23, 2023 YIELD10 BIOSCIENCE, INC.
November 14, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-33133 YIELD10 BIOSCIEN
November 14, 2022	EX-99.1	Yield10 Bioscience Announces Third Quarter 2022 Financial Results -Grower contracts in place for winter 2022/2023 -Development of herbicide tolerance traits in Camelina on track -Collaboration with Rothamsted Research for omega-3 technology extended Yield10 Bioscience Announces Third Quarter 2022 Financial Results -Grower contracts in place for winter 2022/2023 -Development of herbicide tolerance traits in Camelina on track -Collaboration with Rothamsted Research for omega-3 technology extended through 2023 -Management will host a conference call today at 4:30 p.
November 14, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 14, 2022 YIELD10 BIOSCIENCE, INC.
October 5, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 5, 2022 YIELD10 BIOSCIENCE, INC.
October 5, 2022	EX-99.1	Yield10 Bioscience Appoints Willie Loh, Ph.D., Former Cargill Executive, to the Board of Directors Yield10 Bioscience Appoints Willie Loh, Ph.D., Former Cargill Executive, to the Board of Directors WOBURN, Mass. ? Oct. 5, 2022 ? Yield10 Bioscience, Inc. (Nasdaq:YTEN) (?Yield10? or the ?Company?), an agricultural bioscience company, today announced that Willie Loh, Ph.D., was named to the Company?s Board of Directors effective October 4, 2022. Dr. Loh previously served as a Special Commercial an
August 10, 2022	EX-99.1	Yield10 Bioscience Announces Second Quarter 2022 Financial Results -Winter program targeting more than 1,000 acres through grower contracts -On track to achieve key 2022 goal of identifying herbicide tolerant Camelina lines for seed scale up and comm Yield10 Bioscience Announces Second Quarter 2022 Financial Results -Winter program targeting more than 1,000 acres through grower contracts -On track to achieve key 2022 goal of identifying herbicide tolerant Camelina lines for seed scale up and commercial development -Management will host a conference call today at 4:30 p.
August 10, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 10, 2022 YIELD10 BIOSCIENCE, INC.
August 10, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-33133 YIELD10 BIOSCIENCE, I
May 26, 2022	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 25, 2022 YIELD10 BIOSCIENCE, INC.
May 11, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-33133 YIELD10 BIOSCIENCE,
May 11, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 11, 2022 YIELD10 BIOSCIENCE, INC.
May 11, 2022	EX-99.1	Yield10 Bioscience Announces First Quarter 2022 Financial Results -Management will host a conference call today at 4:30 p.m. (ET) to review financial results and provide a corporate update Yield10 Bioscience Announces First Quarter 2022 Financial Results -Management will host a conference call today at 4:30 p.
May 6, 2022	S-8	As filed with the Securities and Exchange Commission on May 6, 2022 As filed with the Securities and Exchange Commission on May 6, 2022 Registration No.
May 6, 2022	EX-FILING FEES	Calculation of Filing Fee Tables Form S-8 (Form Type) Yield10 Bioscience, Inc. (Exact name of Registrant as Specified in its Charter) Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Yield10 Bioscience, Inc.
April 8, 2022	SC 13G/A	YTEN / Yield10 Bioscience Inc / HIRSCHMAN ORIN Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Amendment No. 2 Under the Securities Exchange Act of 1934 Yield10 Bioscience, Inc. (Name of Issuer) Common Stock, $.01 Par Value Per Share (Title of Class of Securities) 98585K862 (CUSIP Number) April 7, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule
March 29, 2022	DEF 14A	ve Proxy Statement on Schedule 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin
March 25, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTI 40Use these links to rapidly review the document TABLE OF CONTENTS Index to Consolidated Financial Statements UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
March 9, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 9, 2022 YIELD10 BIOSCIENCE, INC.
March 9, 2022	EX-99.1	Yield10 Bioscience Announces Fourth Quarter and Full Year 2021 Financial Results -Near-term commercial focus on the Renewable Diesel market -Management will host a conference call today at 4:30 p.m. (ET) to review financial results and provide a corp Yield10 Bioscience Announces Fourth Quarter and Full Year 2021 Financial Results -Near-term commercial focus on the Renewable Diesel market -Management will host a conference call today at 4:30 p.
February 11, 2022	SC 13G/A	YTEN / Yield10 Bioscience Inc / HIRSCHMAN ORIN Passive Investment SC 13G/A 1 formsc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Amendment No. 1 Under the Securities Exchange Act of 1934 Yield10 Bioscience, Inc. (Name of Issuer) Common Stock, $.01 Par Value Per Share (Title of Class of Securities) 98585K862 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropri
February 4, 2022	SC 13G/A	YTEN / Yield10 Bioscience Inc / Hudson Bay Capital Management LP - YTEN 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Yield10 Bioscience, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 98585K862 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua
November 10, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 10, 2021 YIELD10 BIOSCIENCE, INC.
November 10, 2021	EX-99.1	Yield10 Bioscience Announces Third Quarter 2021 Financial Results Management will Host a Conference Call Today at 4:30 p.m. (ET) to Review Financial Results and Provide a Corporate Update Yield10 Bioscience Announces Third Quarter 2021 Financial Results Management will Host a Conference Call Today at 4:30 p.
November 10, 2021	EX-3.1	Amended and Restated By-laws of the Registrant. Exhibit 3.1 AMENDED AND RESTATED BY-LAWS OF YIELD10 BIOSCIENCE, INC. (the ?Corporation?) ARTICLE I Stockholders SECTION 1.Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these By-laws as an ?Annual Meeting?) shall be held at the hour, date and place within or without the United States which is fixed by the Board of Directors, which time, date and place may
November 10, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-33133 YIELD10 BIOSCIEN
September 29, 2021	EX-3.1	AMENDMENT NO. 1 TO AMENDED AND RESTATED BY-LAWS YIELD10 BIOSCIENCE, INC. Exhibit 3.1 AMENDMENT NO. 1 TO AMENDED AND RESTATED BY-LAWS OF YIELD10 BIOSCIENCE, INC. Article VI of the Amended and Restated By-laws of Yield10 Bioscience, Inc. is hereby amended to add Section 11 to Article VI as follows: SECTION 11. Exclusive Forum Provision. Unless the Corporation consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or,
September 29, 2021	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 28, 2021 YIELD10 BIOSCIENCE, INC.
August 11, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 11, 2021 YIELD10 BIOSCIENCE, INC.
August 11, 2021	EX-10.1	Amended and Restated 2018 Stock Option and Incentive Plan. Exhibit 10.1 YIELD10 BIOSCIENCE, INC. AMENDED AND RESTATED 2018 STOCK OPTION AND INCENTIVE PLAN 1.DEFINITIONS. Unless otherwise specified or unless the context otherwise requires, the following terms, as used in this Yield10 Bioscience, Inc. 2018 Stock Option and Incentive Plan, have the following meanings: Administrator means the Board of Directors, unless it has delegated power to act on its beh
August 11, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-33133 YIELD10 BIOSCIENCE, I
August 11, 2021	EX-99.1	Yield10 Bioscience Announces Second Quarter 2021 Financial Results Management will Host a Conference Call Today at 4:30 p.m. (ET) to Review Financial Results and Provide a Corporate Update Yield10 Bioscience Announces Second Quarter 2021 Financial Results Management will Host a Conference Call Today at 4:30 p.
June 7, 2021	S-8	As filed with the Securities and Exchange Commission on June 7, 2021 As filed with the Securities and Exchange Commission on June 7, 2021 Registration No.
May 25, 2021	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 24, 2021 YIELD10 BIOSCIENCE, INC.
May 11, 2021	EX-99.1	Yield10 Bioscience Announces First Quarter 2021 Financial Results Management will host a conference call today at 4:30 p.m. (ET) to review financial results and provide a corporate update Yield10 Bioscience Announces First Quarter 2021 Financial Results Management will host a conference call today at 4:30 p.
May 11, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 11, 2021 YIELD10 BIOSCIENCE, INC.
May 11, 2021	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-33133 YIELD10 BIOSCIENCE,
March 31, 2021	CORRESP	- Yield10 Bioscience, Inc. 19 Presidential Way Woburn, Massachusetts 01801 March 31, 2021 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Charles Eastman, Staff Accountant Re: Yield10 Bioscience, Inc. Registration Statement on Form S-3 File No. 333-254830 Request for Acceleration Dear Mr. Eastman: Pursuant to Rule
March 29, 2021	S-8	- S-8 As filed with the Securities and Exchange Commission on March 29, 2021 Registration No.
March 29, 2021	DEF 14A	Schedule 14A for the annual meeting of our stockholders to be held on May UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin
March 29, 2021	S-3	- S-3 As filed with the Securities and Exchange Commission on March 29, 2021 Registration No.
March 16, 2021	EX-23.1`	CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 23.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in the Registration Statements on Form S-1 (No. 333-237420 and 333-249388), Form S-3 (No.333-217051 and 333-237539) and Form S-8 (No. 333-138631, 333-145232, 333-155115, 333-157869, 333-165405, 333-172724, 333-181268, 333-187589, 333-194858, 333-194859, 333-202983, 333-217052, 333-226
March 16, 2021	EX-99.1	Yield10 Bioscience Announces Fourth Quarter and Full Year 2020 Financial Results Management will host a conference call today at 4:30 p.m. (ET) to review financial results and provide a corporate update Yield10 Bioscience Announces Fourth Quarter and Full Year 2020 Financial Results Management will host a conference call today at 4:30 p.
March 16, 2021	EX-4.1	DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Exhibit 4.1 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Yield10 Bioscience, Inc. (the ?Company? or ?we?) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common stock, par value $0.01 per share. DESCRIPTION OF COMMON STOCK The following description of our common st
March 16, 2021	EX-21.1	Subsidiaries of the Registrant. Exhibit 21.1 Subsidiaries of the Registrant Subsidiary Name Jurisdiction of Organization Yield10 Bioscience Securities Corp. MA Metabolix Oilseeds, Inc. Canada
March 16, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 yten-q4x2020x8kearnings.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 16, 2021 YIELD10 BIOSCIENCE, INC. (Exact Name of Registrant as Specified in Its Charter) DELAWARE (State or Other Jurisdiction of Incorporatio
March 16, 2021	10-K	Annual Report - 10-K 40Use these links to rapidly review the document TABLE OF CONTENTS Index to Consolidated Financial Statements UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
February 11, 2021	SC 13G	Yield10 Bioscience, Inc. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* Yield10 Bioscience, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 98585K862 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant t
February 5, 2021	SC 13D/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 7)* Yield10 Bioscience, Inc. (Name of Issuer) Common Stock par value $0.01 per share (Title of Class of Secu UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 7)* Yield10 Bioscience, Inc. (Name of Issuer) Common Stock par value $0.01 per share (Title of Class of Securities) 98585K862 (CUSIP Number) Jack W. Schuler 100 N. Field Drive, Suite 360 Lake Forest, Illinois 60045 (224) 880-1210 (Name, Address and Telephone
February 2, 2021	EX-99.1	Yield10 Bioscience Announces Pricing of $12.7 Million Public Offering Exhibit 99.1 Yield10 Bioscience Announces Pricing of $12.7 Million Public Offering WOBURN, Mass., Jan. 31, 2021 (GLOBE NEWSWIRE) - Yield10 Bioscience, Inc. (Nasdaq: YTEN), an agricultural bioscience company, today announced the pricing of its underwritten public offering of 1,040,000 shares of its common stock at a public offering price of $12.25 per share. The gross proceeds from the public offer
February 2, 2021	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2021 YIELD10 BIOSCIENCE, INC.
February 2, 2021	424B5	1,040,000 Shares Common Stock Yield10 Bioscience, Inc. TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-237539 PROSPECTUS SUPPLEMENT (To Prospectus dated April 10, 2020) 1,040,000 Shares Common Stock Yield10 Bioscience, Inc. We are offering 1,040,000 shares of our common stock, par value $0.01 per share (the “Common Stock”). Our Common Stock is listed on the Nasdaq Capital Market under the symbol “YTEN.” The last rep
February 2, 2021	EX-1.1	Underwriting Agreement, dated as of January 31, 2021, by and between Yield10 Bioscience, Inc. and Maxim Group LLC as representative of the several underwriters, if any, named on Schedule I thereto. Exhibit 1.1 YIELD10 BIOSCIENCE, INC. UNDERWRITING AGREEMENT January 31, 2021 Maxim Group LLC 405 Lexington Avenue New York, New York 10174 As Representative of the Underwriters named on Schedule A hereto Ladies and Gentlemen: Yield10 Bioscience, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell an aggregate of 1,040,000 sha
January 29, 2021	424B5	[•] Shares Common Stock Yield10 Bioscience, Inc. TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-237539 PRELIMINARY PROSPECTUS SUPPLEMENT (To Prospectus dated April 10, 2020) [•] Shares Common Stock Yield10 Bioscience, Inc. We are offering [•] shares of our common stock, par value $0.01 per share (the “Common Stock”). Our Common Stock is listed on the Nasdaq Capital Market under the symbol “YTEN.” The last rep
January 19, 2021	SC 13G/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SC 13G/A 1 sc13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Yield10 Bioscience, Inc. (Name of Issuer) Common Stock, par value $0.01 per share. (Title of Class of Securities) 98585K862 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriat
January 19, 2021	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 19, 2021 YIELD10 BIOSCIENCE, INC.
January 19, 2021	EX-99.1	Yield10 Bioscience Announces Achievement of Proof-of-Concept Milestone for Producing PHA Bioplastic in Field Grown Camelina Plants Yield10 Bioscience Announces Achievement of Proof-of-Concept Milestone for Producing PHA Bioplastic in Field Grown Camelina Plants WOBURN, Mass.
January 19, 2021	SC 13G	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Yield10 Bioscience, Inc. (Name of Issuer) Common Stock, $.01 Par Value Per Share (Title of Class of Securities) 98585K862 (CUSIP Number) January 15, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whi
November 12, 2020	EX-4.1	Specimen Stock Certificate for shares of the Registrant’s Common Stock. Exhibit 4
November 12, 2020	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2020 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-33133 YIELD10 BIOSCIEN
November 12, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 12, 2020 YIELD10 BIOSCIENCE, INC.
November 12, 2020	EX-99.1	Yield10 Bioscience Announces Third Quarter 2020 Financial Results Yield10 Bioscience Announces Third Quarter 2020 Financial Results WOBURN, Mass. - November 12, 2020 - Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company, today reported financial results for the three and nine months ended September 30, 2020. "We are very pleased with our strong progress across multiple fronts in the third quarter and beyond," said Oliver Peoples, Ph.D., Pr
November 12, 2020	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 12, 2020 YIELD10 BIOSCIENCE, INC.
November 12, 2020	EX-99.1	Yield10 Bioscience Announces Collaboration with Rothamsted Research to Develop Advanced Technology for Producing Omega-3 Nutritional Oils in Camelina Yield10 Bioscience Announces Collaboration with Rothamsted Research to Develop Advanced Technology for Producing Omega-3 Nutritional Oils in Camelina WOBURN, Mass.
October 19, 2020	424B4	YIELD10 BIOSCIENCE, INC. 396,450 SHARES OF COMMON STOCK Filed Pursuant to Rule 424(b)(4) Registration No. 333-249388 PROSPECTUS YIELD10 BIOSCIENCE, INC. 396,450 SHARES OF COMMON STOCK This prospectus relates to the proposed resale of up to 396,450 shares of Yield10 Bioscience, Inc. (the “Company”), common stock, $0.01 par value per share. These shares will be resold from time to time by the entities or individuals listed in the section titled “Selling
October 13, 2020	CORRESP	- Yield10 Bioscience, Inc. 19 Presidential Way, Suite 201 Woburn, Massachusetts 01801 October 13, 2020 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Sergio Chinos, Esq. Re: Yield10 Bioscience, Inc. Registration Statement on Form S-1 File No. 333 249388 Request for Acceleration Dear Mr. Chinos: Pursuant to Rule 4
October 8, 2020	S-1	Registration Statement - S-1 S-1 1 ytens-1100820schulerresale.htm S-1 As filed with the Securities and Exchange Commission on October 8, 2020 Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM S‑1 REGISTRATION STATEMENT under the SECURITIES ACT OF 1933 YIELD10 BIOSCIENCE, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 2870 04-3158289 (State or other
August 31, 2020	SC 13G	98585K862 / YIELD10 BIOSCIENCE INC / Lind Global Macro Fund LP Passive Investment SC 13G 1 sc13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Yield10 Bioscience, Inc. (Name of Issuer) Common Stock, par value $0.01 per share. (Title of Class of Securities) 98585K862 (CUSIP Number) August 28, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box
August 31, 2020	SC 13D/A	98585K862 / YIELD10 BIOSCIENCE INC / SCHULER JACK W - SCHEDULE 13D/A Activist Investment SC 13D/A 1 tm2029838-1sc13da.htm SCHEDULE 13D/A CUSIP No. 98585K862 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 6)* Yield10 Bioscience, Inc. (Name of Issuer) Common Stock par value $0.01 per share (Title of Class of Securities) 98585K862 (CUSIP Number) Jack W. Schuler 100 N. Field Drive, Suite 360 Lak
August 31, 2020	EX-99.1	JOINT FILING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the Common Stock, par value $0.01 per share, of Yield10 Bioscience, Inc. shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule 13G. August 31, 2020 LIND GLOBAL MACRO FUND, LP By: Lind Global Partners L
August 25, 2020	EX-1.1	Underwriting Agreement, dated as of August 22, 2020, by and between Yield10 Bioscience, Inc. and Maxim Group LLC as representative of the several underwriters, if any, named on Schedule I thereto. Exhibit 1.1 YIELD10 BIOSCIENCE, INC. UNDERWRITING AGREEMENT August 22, 2020 Maxim Group LLC 405 Lexington Avenue New York, New York 10174 As Representative of the Underwriters named on Schedule A hereto Ladies and Gentlemen: Yield10 Bioscience, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell an aggregate of 835,000 shares
August 25, 2020	424B5	835,000 Shares Common Stock Yield10 Bioscience, Inc. Use these links to rapidly review the document TABLE OF CONTENTS Prospectus Supplement Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No.
August 25, 2020	EX-99.1	Yield10 Bioscience Announces Pricing of $5.2 Million Public Offering and Concurrent Private Placement Exhibit 99.1 Yield10 Bioscience Announces Pricing of $5.2 Million Public Offering and Concurrent Private Placement WOBURN, Mass., Aug. 22, 2020 (GLOBENEWSWIRE) - Yield10 Bioscience, Inc. (Nasdaq: YTEN), an agricultural bioscience company, today announced the pricing of its underwritten public offering of 835,000 shares of its common stock at a public offering price of $4.25 per share. The gross pr
August 25, 2020	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 22, 2020 YIELD10 BIOSCIENCE, INC.
August 25, 2020	EX-10.1	Securities Purchase Agreement, dated as of August 22, 2020, by and between Yield10 Bioscience, Inc. and the Investors listed on Schedule I thereto. Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) dated August 22, 2020, is entered into by and among (i) Yield10 Bioscience, Inc., a Delaware corporation (the “Company”), and (ii) each person listed on Schedule I hereto (each, an “Investor” and collectively, the “Investors”). WHEREAS, subject to the terms and conditions set forth in this Agreement, t
August 21, 2020	424B5	PRELIMINARY PROSPECTUS SUPPLEMENT (To Prospectus dated April 10, 2020) [ · ] Shares Common Stock Yield10 Bioscience, Inc. 424B5 1 a2242305z424b5.htm 424B5 Use these links to rapidly review the document TABLE OF CONTENTS Prospectus Supplement Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-237539 PRELIMINARY PROSPECTUS SUPPLEMENT (To Prospectus dated April 10, 2020) [ · ] Shares Common Stock Yield10 Bioscience, Inc. We are offering [ · ] shares of our common stock, par value $0.01 per
August 11, 2020	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended June 30, 2020 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-33133 YIELD10 BIOSCIENCE, I
August 11, 2020	EX-99.1	Yield10 Bioscience Signs Research Agreement with GDM to Evaluate New Yield Traits in Soybean Yield10 Bioscience Signs Research Agreement with GDM to Evaluate New Yield Traits in Soybean WOBURN, Mass.
August 11, 2020	EX-99.1	Yield10 Bioscience Announces Second Quarter 2020 Financial Results Yield10 Bioscience Announces Second Quarter 2020 Financial Results WOBURN, Mass. - August 11, 2020 - Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company, today reported financial results for the three and six months ended June 30, 2020. "The Yield10 team has made good progress executing on our strategic plans for 2020 and beyond," said Oliver Peoples, Ph.D., president and ch
August 11, 2020	EX-10.1	Yield10 Bioscience, Inc. Amended and Restated 2018 Stock Option and Incentive Plan (filed as Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-33133) on August 11, 2021 and incorporated herein by reference) Exhibit 10.1 YIELD10 BIOSCIENCE, INC. AMENDED AND RESTATED 2018 STOCK OPTION AND INCENTIVE PLAN 1. DEFINITIONS. Unless otherwise specified or unless the context otherwise requires, the following terms, as used in this Yield10 Bioscience, Inc. 2018 Stock Option and Incentive Plan, have the following meanings: Administrator means the Board of Directors, unless it has delegated power to act on its be
August 11, 2020	8-K	Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 11, 2020 YIELD10 BIOSCIENCE, INC.
August 11, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 11, 2020 YIELD10 BIOSCIENCE, INC.
June 9, 2020	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 9, 2020 YIELD10 BIOSCIENCE, INC.
May 29, 2020	S-8	- S-8 As filed with the Securities and Exchange Commission on May 29, 2020 Registration No.
May 20, 2020	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 19, 2020 YIELD10 BIOSCIENCE, INC.
May 15, 2020	EX-10.1	U.S. SMALL BUSINESS ADMINISTRATION PAYCHECK PROTECTION NOTE EX-10.1 2 ex-101x20200331xpppnote.htm EXHIBIT 10.1 Exhibit 10.1 U.S. SMALL BUSINESS ADMINISTRATION PAYCHECK PROTECTION NOTE SBA Loan # 1296737200 SBA Loan Name Yield10 Bioscience, Inc. Date 4/17/2020 Loan Amount $332,800.00 Fixed Interest Rate 1.0% Borrower YIELD10 BIOSCIENCE, INC. Lender Citizens Bank N.A. 1 Citizens Plaza Providence, RI 02903 1. PROMISE TO PAY: In return for the Loan, Borrower p
May 15, 2020	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2020 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-33133 YIELD10 BIOSCIENCE,
May 14, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 14, 2020 YIELD10 BIOSCIENCE, INC.
May 14, 2020	EX-99.1	Yield10 Bioscience Announces First Quarter 2020 Financial Results EX-99.1 2 exhibit991yten-20200512x8k.htm EXHIBIT 99.1 Yield10 Bioscience Announces First Quarter 2020 Financial Results WOBURN, Mass. - May 14, 2020 - Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company, today reported financial results for the three months ended March 31, 2020. “In the first quarter, we prioritized focus on activities relating to our 2020 Field Testing prog
May 6, 2020	DEFA14A	Proxy Statement on Schedule 14A for the annual meeting of stockholders to be held on May 19, 2020 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin
April 8, 2020	CORRESP	- Yield10 Bioscience, Inc. 19 Presidential Way Woburn, Massachusetts 01801 April 8, 2020 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Sergio Chinos, Esq. Re: Yield10 Bioscience, Inc. Registration Statement on Form S-3 File No. 333 237539 Request for Acceleration Dear Mr. Chinos: Pursuant to Rule 461 of Regulati
April 3, 2020	424B4	YIELD10 BIOSCIENCE, INC. 2,156,250 SHARES OF COMMON STOCK Filed Pursuant to Rule 424(b)(4) Registration No. 333-237420 PROSPECTUS YIELD10 BIOSCIENCE, INC. 2,156,250 SHARES OF COMMON STOCK This prospectus relates to the proposed resale of up to 2,156,250 shares of Yield10 Bioscience, Inc. (the “Company”), common stock, $0.01 par value per share, as follows: (i) an aggregate of up to 718,750 shares of common stock that were issued upon the conversion of th
April 1, 2020	S-3	MBLX / Metabolix, Inc. S-3 - - S-3 As filed with the Securities and Exchange Commission on April 1, 2020 Registration No.
March 30, 2020	CORRESP	- Yield10 Bioscience, Inc. 19 Presidential Way Woburn, Massachusetts 01801 March 30, 2020 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Sergio Chinos, Esq. Re: Yield10 Bioscience, Inc. Registration Statement on Form S-1 File No. 333 237420 Request for Acceleration Dear Mr. Chinos: Pursuant to Rule 461 of Regulat
March 27, 2020	S-1	MBLX / Metabolix, Inc. S-1 - Registration Statement - S-1 As filed with the Securities and Exchange Commission on March 26, 2020 Registration Statement No.
March 25, 2020	DEF 14A	Definitive Proxy Statement on Schedule 14A for the annual meeting of our stockholders to be held on May 19, 2020 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ý Defin
March 25, 2020	EX-4.1	Description of Securities of the Registrant. Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Yield10 Bioscience, Inc. (the “Company” or “we”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common stock, par value $0.01 per share. DESCRIPTION OF COMMON STOCK We are authorized to issue 60,000,000 shar
March 25, 2020	10-K	2019 Consolidated Financial Statements 40Use these links to rapidly review the document TABLE OF CONTENTS Index to Consolidated Financial Statements UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
March 25, 2020	EX-10.2.6	2018 Stock Option and Incentive Plan, Form of Restricted Stock Unit Agreement. EX-10.2.6 3 yten-20191231x10kexh10262.htm EXHIBIT 10.2.6 Exhibit 10.2.6 YIELD10 BIOSCIENCE, INC. Restricted Stock Unit Award Grant Notice Restricted Stock Unit Award Grant under the Company’s 2018 Stock Option and Incentive Plan 1. Name and Address of Participant: 2. Date of Grant of Restricted Stock Unit Award: 3. Maximum Number of Shares underlying Restricted Stock Unit Award: 4. Vesting of Awar
March 19, 2020	EX-99.1	Yield10 Bioscience Announces Fourth Quarter and Full Year 2019 Financial Results EX-99.1 2 exhibit991yten-20200319x8k.htm EXHIBIT 99.1 Yield10 Bioscience Announces Fourth Quarter and Full Year 2019 Financial Results WOBURN, Mass. - March 19, 2020 - Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company, today reported financial results for the three and twelve months ended December 31, 2019. "In 2019 we consistently met our milestones as we brought forward
March 19, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 19, 2020 YIELD10 BIOSCIENCE, INC.
February 13, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 31, 2020 YIELD10 BIOSCIENCE, INC.
February 13, 2020	SC 13D/A	MBLX / Metabolix, Inc. / SCHULER JACK W - SC 13D/A Activist Investment CUSIP No. 98585K862 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* Yield10 Bioscience, Inc. (Name of Issuer) Common Stock par value $0.01 per share (Title of Class of Securities) 98585K862 (CUSIP Number) Jack W. Schuler 100 N. Field Drive, Suite 360 Lake Forest, Illinois 60045 (224) 880-1210 (Name, A
February 13, 2020	EX-99.1	Yield10 Bioscience Appoints Agriculture Industry Veteran Sherri M. Brown, Ph.D., to Board of Directors Yield10 Bioscience Appoints Agriculture Industry Veteran Sherri M. Brown, Ph.D., to Board of Directors WOBURN, Mass. – February 13, 2020 – Yield10 Bioscience, Inc. (Nasdaq:YTEN) today announced that Sherri M. Brown, Ph.D. was appointed to the Company’s Board of Directors effective February 11, 2020. In connection with her appointment, Dr. Brown will serve as chair of a newly formed Science and Tec
February 6, 2020	SC 13D/A	YTEN / Yield10 Bioscience, Inc. / SCHULER JACK W - SCHEDULE 13D/A Activist Investment CUSIP No. 98585K862 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* Yield10 Bioscience, Inc. (Name of Issuer) Common Stock par value $0.01 per share (Title of Class of Securities) 98585K862 (CUSIP Number) Jack W. Schuler 100 N. Field Drive, Suite 360 Lake Forest, Illinois 60045 (224) 880-1210 (Name, A
January 31, 2020	EX-99.1	Yield10 Bioscience Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement Yield10 Bioscience Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement WOBURN, Mass.
January 31, 2020	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 31, 2020 YIELD10 BIOSCIENCE, INC.
January 28, 2020	SC 13G/A	MBLX / Metabolix, Inc. / Empery Asset Management, LP - YIELD10 BIOSCIENCE, INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Yield10 Bioscience, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 98585K201 (CUSIP Number) December 31, 2019 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which
January 15, 2020	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 15, 2020 YIELD10 BIOSCIENCE, INC.
January 15, 2020	EX-99.1	Yield10 Bioscience Announces 1-for-40 Reverse Stock Split EX-99.1 3 exhibit991011520.htm EXHIBIT 99.1 Exhibit 99.1 Yield10 Bioscience Announces 1-for-40 Reverse Stock Split WOBURN, Mass. - January 15, 2020 - Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company that uses its “Trait Factory” to develop high value seed traits for the agriculture and food industries, today announced that it will effect a 1-for-40 reverse stock split of
January 15, 2020	EX-3.1	Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Registrant. Exhibit 3.1 CERTIFICATE OF AMENDMENT TO EFFECT REVERSE STOCK SPLIT Pursuant to Section 242 of the General Corporation Law of the State of Delaware, Yield10 Bioscience, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), does hereby certify as follows: 1.The name of the Corporation is Yield10 Bioscience, Inc. 2.The Board of Directors of the Corpor
January 9, 2020	S-8	YTEN / Yield10 Bioscience, Inc. S-8 - - S-8 As filed with the Securities and Exchange Commission on January 8, 2020 Registration No.

YTEN / Yield10 Bioscience, Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

Mga Batayang Estadistika

SEC Filings

SEC Filings (Chronological Order)

Other Listings